{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:17:08Z","timestamp":1786979828241,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00228-022-03381-4","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T09:06:58Z","timestamp":1663060018000},"page":"1749-1761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Daridorexant for the treatment of insomnia disorder: findings and implications"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-0658","authenticated-orcid":false,"given":"J\u00e9ssica Barreto Ribeiro","family":"dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2550-7249","authenticated-orcid":false,"given":"Michael Ruberson Ribeiro","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"issue":"5","key":"3381_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","volume":"146","author":"MJ Sateia","year":"2014","unstructured":"Sateia MJ (2014) International classification of sleep disorders-third edition: highlights and modifications. Chest 146(5):1387\u20131394. https:\/\/doi.org\/10.1378\/chest.14-0970","journal-title":"Chest"},{"issue":"5 Suppl","key":"3381_CR2","first-page":"S7","volume":"3","author":"T Roth","year":"2007","unstructured":"Roth T (2007) Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med: JCSM: Official Pub Am Acad Sleep Med 3(5 Suppl):S7\u2013S10","journal-title":"J Clin Sleep Med: JCSM: Official Pub Am Acad Sleep Med"},{"key":"3381_CR3","doi-asserted-by":"publisher","unstructured":"Ford ES, Cunningham TJ, Giles WH, Croft JB (2015) Trends in insomnia and excessive daytime sleepiness among U.S. adults from 2002 to 2012. Sleep Med 16(3), 372\u2013378. https:\/\/doi.org\/10.1016\/j.sleep.2014.12.008","DOI":"10.1016\/j.sleep.2014.12.008"},{"issue":"3","key":"3381_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.5665\/sleep.1700","volume":"35","author":"M Calem","year":"2012","unstructured":"Calem M, Bisla J, Begum A, Dewey M, Bebbington PE, Brugha T, Cooper C, Jenkins R, Lindesay J, McManus S, Meltzer H, Spiers N, Weich S, Stewart R (2012) Increased prevalence of insomnia and changes in hypnotics use in England over 15 years: analysis of the 1993, 2000, and 2007 National Psychiatric Morbidity Surveys. Sleep 35(3):377\u2013384. https:\/\/doi.org\/10.5665\/sleep.1700","journal-title":"Sleep"},{"key":"3381_CR5","doi-asserted-by":"publisher","unstructured":"Olfson M, Wall M, Liu SM, Morin CM, Blanco C (2018) Insomnia and impaired quality of life in the United States. J Clin Psych 79(5):17m12020. https:\/\/doi.org\/10.4088\/JCP.17m12020","DOI":"10.4088\/JCP.17m12020"},{"issue":"2","key":"3381_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5664\/jcsm.8986","volume":"17","author":"JD Edinger","year":"2021","unstructured":"Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, Sateia MJ, Troxel WM, Zhou ES, Kazmi U, Heald JL, Martin JL (2021) Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med: JCSM: Official Pub Am Acad Sleep Med 17(2):255\u2013262. https:\/\/doi.org\/10.5664\/jcsm.8986","journal-title":"J Clin Sleep Med: JCSM: Official Pub Am Acad Sleep Med"},{"issue":"2","key":"3381_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017) Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med: JCSM: Official Pub Am Acad Sleep Med 13(2):307\u2013349. https:\/\/doi.org\/10.5664\/jcsm.6470","journal-title":"J Clin Sleep Med: JCSM: Official Pub Am Acad Sleep Med"},{"key":"3381_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fphar.2013.00163","volume":"4","author":"AC Equihua","year":"2013","unstructured":"Equihua AC, De La Herr\u00e1n-Arita AK, Drucker-Colin R (2013) Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol 4:163. https:\/\/doi.org\/10.3389\/fphar.2013.00163","journal-title":"Front Pharmacol"},{"issue":"7526","key":"3381_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/bmj.38623.768588.47","volume":"331","author":"J Glass","year":"2005","unstructured":"Glass J, Lanct\u00f4t KL, Herrmann N, Sproule BA, Busto UE (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ (Clinical research ed) 331(7526):1169. https:\/\/doi.org\/10.1136\/bmj.38623.768588.47","journal-title":"BMJ (Clinical research ed)"},{"issue":"11","key":"3381_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2165\/00002512-200320110-00004","volume":"20","author":"MJ Panneman","year":"2003","unstructured":"Panneman MJ, Goettsch WG, Kramarz P, Herings RM (2003) The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a Pharmo study. Drugs Aging 20(11):833\u2013839. https:\/\/doi.org\/10.2165\/00002512-200320110-00004","journal-title":"Drugs Aging"},{"issue":"1","key":"3381_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/157488606775252674","volume":"1","author":"JC Verster","year":"2006","unstructured":"Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER (2006) Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf 1(1):63\u201371. https:\/\/doi.org\/10.2174\/157488606775252674","journal-title":"Curr Drug Saf"},{"issue":"11","key":"3381_CR12","first-page":"759","volume":"40","author":"JD Lie","year":"2015","unstructured":"Lie JD, Tu KN, Shen DD, Wong BM (2015) Pharmacological treatment of insomnia. P & T: Peer-Rev J Formulary Manag 40(11):759\u2013771","journal-title":"P & T: Peer-Rev J Formulary Manag"},{"key":"3381_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8343","volume":"345","author":"TB Huedo-Medina","year":"2012","unstructured":"Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (2012) Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ (Clinical research ed) 345:e8343. https:\/\/doi.org\/10.1136\/bmj.e8343","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"3381_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12877-022-02757-6","volume":"22","author":"V Scharner","year":"2022","unstructured":"Scharner V, Hasieber L, S\u00f6nnichsen A, Mann E (2022) Efficacy and safety of Z-substances in the management of insomnia in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr 22(1):87. https:\/\/doi.org\/10.1186\/s12877-022-02757-6","journal-title":"BMC Geriatr"},{"key":"3381_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000514963","volume":"45","author":"Y Sun","year":"2021","unstructured":"Sun Y, Tisdale RK, Kilduff TS (2021) Hypocretin\/orexin receptor pharmacology and sleep phases. Front Neurol Neurosci 45:22\u201337. https:\/\/doi.org\/10.1159\/000514963","journal-title":"Front Neurol Neurosci"},{"issue":"8","key":"3381_CR16","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/0269881112448946","volume":"26","author":"P Hoever","year":"2012","unstructured":"Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J (2012) Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol (Oxford, England) 26(8):1071\u20131080. https:\/\/doi.org\/10.1177\/0269881112448946","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"key":"3381_CR17","unstructured":"Food And Drug Administration (2014) Suvorexant (Belsomra). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204569s000lbledt.pdf. Accessed 20 Jan 2022"},{"issue":"2","key":"3381_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","volume":"79","author":"WJ Herring","year":"2016","unstructured":"Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D (2016) Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiat 79(2):136\u2013148. https:\/\/doi.org\/10.1016\/j.biopsych.2014.10.003","journal-title":"Biol Psychiat"},{"key":"3381_CR19","unstructured":"Food And Drug Administration (2019) Lemborexant (Dayvigo). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212028s000lbl.pdf. Accessed 20 Jan 2022"},{"issue":"12","key":"3381_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","volume":"2","author":"R Rosenberg","year":"2019","unstructured":"Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M (2019) Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open 2(12):e1918254. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18254","journal-title":"JAMA Netw Open"},{"key":"3381_CR21","unstructured":"Food And Drug Administration (2022) Daridorexant (Quviviq). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214985s000lbl.pdf. Accessed 20 Jan 2022"},{"issue":"2","key":"3381_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","volume":"21","author":"E Mignot","year":"2022","unstructured":"Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti C, Pain S, Kinter DS, Roth T, Investigators (2022) Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. The Lancet Neurol 21(2):125\u2013139. https:\/\/doi.org\/10.1016\/S1474-4422(21)00436-1","journal-title":"The Lancet Neurol"},{"key":"3381_CR23","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"key":"3381_CR24","unstructured":"ClinicalTrials.gov (2022) Daridorexant. https:\/\/clinicaltrials.gov. Accessed 20 Jan 2022"},{"issue":"10","key":"3381_CR25","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51(10):2778\u20132786. https:\/\/doi.org\/10.1021\/ci200227u","journal-title":"J Chem Inf Model"},{"issue":"W1","key":"3381_CR26","doi-asserted-by":"publisher","first-page":"W48","DOI":"10.1093\/nar\/gkaa235","volume":"48","author":"K Sch\u00f6ning-Stierand","year":"2020","unstructured":"Sch\u00f6ning-Stierand K, Diedrich K, F\u00e4hrrolfes R, Flachsenberg F, Meyder A, Nittinger E, Steinegger R, Rarey M (2020) ProteinsPlus: interactive analysis of protein-ligand binding interfaces. Nucleic Acids Res 48(W1):W48\u2013W53. https:\/\/doi.org\/10.1093\/nar\/gkaa235","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"3381_CR27","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1021\/acs.jmedchem.9b01787","volume":"63","author":"M Rappas","year":"2020","unstructured":"Rappas M, Ali A, Bennett KA, Brown JD, Bucknell SJ, Congreve M, Cooke RM, Cseke G, de Graaf C, Dor\u00e9 AS, Errey JC, Jazayeri A, Marshall FH, Mason JS, Mould R, Patel JC, Tehan BG, Weir M, Christopher JA (2020) Comparison of Orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysis. J Med Chem 63(4):1528\u20131543. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01787","journal-title":"J Med Chem"},{"key":"3381_CR28","unstructured":"Boss C, Brotschi C, Heidmann B, Siffer-Len T, Von Raumer M, Williams JT, Inventors Actelion Pharmaceuticals Ltd, assignee (2015) Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]idazol-2-yl)-2-methyl-pyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone. World Intellectual Property Organization WO2015\/083071. https:\/\/patentimages.storage.googleapis.com\/d5\/d3\/39\/00652f0a716d1f\/WO2015083071A1.pdf. Accessed 20 Jan 2022"},{"issue":"5","key":"3381_CR29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cpt.1046","volume":"104","author":"C Muehlan","year":"2018","unstructured":"Muehlan C, Heuberger J, Juif PE, Croft M, van Gerven J, Dingemanse J (2018) Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther 104(5):1022\u20131029. https:\/\/doi.org\/10.1002\/cpt.1046","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"3381_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","volume":"29","author":"C Muehlan","year":"2019","unstructured":"Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J (2019) Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 29(7):847\u2013857. https:\/\/doi.org\/10.1016\/j.euroneuro.2019.05.009","journal-title":"Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol"},{"key":"3381_CR31","unstructured":"European Medicines Agency (2022) Assessment report EMA\/187589\/2022. Quviviq. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/quviviq-epar-public-assessment-report_en.pdf. Accessed 26 Aug 2022"},{"issue":"2","key":"3381_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/JCP.0000000000001182","volume":"40","author":"C Muehlan","year":"2020","unstructured":"Muehlan C, Zuiker R, Peeters P, Rowles R, Dingemanse J (2020) Pharmacokinetics and pharmacodynamics of the dual orexin receptor antagonist daridorexant in Japanese and Caucasian subjects. J Clin Psychopharmacol 40(2):157\u2013166. https:\/\/doi.org\/10.1097\/JCP.0000000000001182","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"3381_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/0269881119882854","volume":"34","author":"C Muehlan","year":"2020","unstructured":"Muehlan C, Boehler M, Brooks S, Zuiker R, van Gerven J, Dingemanse J (2020) Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. J Psychopharmacol (Oxford, England) 34(3):326\u2013335. https:\/\/doi.org\/10.1177\/0269881119882854","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"10","key":"3381_CR34","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40262-021-01028-8","volume":"60","author":"B Berger","year":"2021","unstructured":"Berger B, Dingemanse J, Sabattini G, Delahaye S, Duthaler U, Muehlan C, Kr\u00e4henb\u00fchl S (2021) Effect of liver cirrhosis on the pharmacokinetics, metabolism, and tolerability of daridorexant, a novel dual orexin receptor antagonist. Clin Pharmacokinet 60(10):1349\u20131360. https:\/\/doi.org\/10.1007\/s40262-021-01028-8","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3381_CR35","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/cts.13079","volume":"14","author":"B Berger","year":"2021","unstructured":"Berger B, Muehlan C, Klein G, Dingemanse J (2021) Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment. Clin Transl Sci 14(6):2132\u20132138. https:\/\/doi.org\/10.1111\/cts.13079","journal-title":"Clin Transl Sci"},{"issue":"2","key":"3381_CR36","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/bcp.15029","volume":"88","author":"M Gehin","year":"2022","unstructured":"Gehin M, Wierdak J, Sabattini G, Sidharta PN, Dingemanse J (2022) Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist. Br J Clin Pharmacol 88(2):810\u2013819. https:\/\/doi.org\/10.1111\/bcp.15029","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"3381_CR37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s40263-020-00768-8","volume":"34","author":"B Berger","year":"2020","unstructured":"Berger B, Brooks S, Zuiker R, Richard M, Muehlan C, Dingemanse J (2020) Pharmacological Interactions between the dual orexin receptor antagonist daridorexant and ethanol in a double-blind, randomized, placebo-controlled, double-dummy, Four-Way Crossover Phase I Study in Healthy Subjects. CNS Drugs 34(12):1253\u20131266. https:\/\/doi.org\/10.1007\/s40263-020-00768-8","journal-title":"CNS Drugs"},{"issue":"11","key":"3381_CR38","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/1440-1681.13370","volume":"47","author":"I Zenklusen","year":"2020","unstructured":"Zenklusen I, Muehlan C, Ulc I, Li\u0161ka J, Dingemanse J (2020) The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. Clin Exp Pharmacol Physiol 47(11):1843\u20131849. https:\/\/doi.org\/10.1111\/1440-1681.13370","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"3381_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.euroneuro.2021.05.005","volume":"51","author":"B Berger","year":"2021","unstructured":"Berger B, Kornberger R, Dingemanse J (2021) Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 51:90\u2013104. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.05.005","journal-title":"Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol"},{"issue":"3","key":"3381_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","volume":"87","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, Hedner J (2020) Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol 87(3):347\u2013356. https:\/\/doi.org\/10.1002\/ana.25680","journal-title":"Ann Neurol"},{"issue":"21","key":"3381_CR41","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","volume":"94","author":"G Zammit","year":"2020","unstructured":"Zammit G, Dauvilliers Y, Pain S, Seb\u00f6k Kinter D, Mansour Y, Kunz D (2020) Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology 94(21):e2222\u2013e2232. https:\/\/doi.org\/10.1212\/WNL.0000000000009475","journal-title":"Neurology"},{"issue":"8","key":"3381_CR42","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40261-021-01062-1","volume":"41","author":"U Schilling","year":"2021","unstructured":"Schilling U, Henrich A, Muehlan C, Krause A, Dingemanse J, Ufer M (2021) Impact of daridorexant, a dual orexin receptor antagonist, on cardiac repolarization following bedtime dosing: results from a thorough QT study using concentration-QT analysis. Clin Drug Investig 41(8):711\u2013721. https:\/\/doi.org\/10.1007\/s40261-021-01062-1","journal-title":"Clin Drug Investig"},{"key":"3381_CR43","doi-asserted-by":"publisher","unstructured":"Boof ML, Dingemanse J, Lederer K, Fietze I, Ufer M (2021) Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 44(6):zsaa275. https:\/\/doi.org\/10.1093\/sleep\/zsaa275","DOI":"10.1093\/sleep\/zsaa275"},{"issue":"4","key":"3381_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13248","volume":"30","author":"ML Boof","year":"2021","unstructured":"Boof ML, Dingemanse J, Brunke M, Esselmann A, Heymer P, Kestermann O, Lederer K, Fietze I, Ufer M (2021) Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. J Sleep Res 30(4):e13248. https:\/\/doi.org\/10.1111\/jsr.13248","journal-title":"J Sleep Res"},{"key":"3381_CR45","doi-asserted-by":"publisher","unstructured":"Ufer M, Kelsh D, Schoedel KA. Dingemanse J (2022) Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep 45(3):zsab224. https:\/\/doi.org\/10.1093\/sleep\/zsab224","DOI":"10.1093\/sleep\/zsab224"},{"issue":"1","key":"3381_CR46","first-page":"68","volume":"116","author":"PC Bollu","year":"2019","unstructured":"Bollu PC, Kaur H (2019) Sleep medicine: insomnia and sleep. Mo Med 116(1):68\u201375","journal-title":"Mo Med"},{"key":"3381_CR47","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.2147\/DDDT.S73224","volume":"9","author":"EL Sutton","year":"2015","unstructured":"Sutton EL (2015) Profile of suvorexant in the management of insomnia. Drug Des Dev Ther 9:6035\u20136042. https:\/\/doi.org\/10.2147\/DDDT.S73224","journal-title":"Drug Des Dev Ther"},{"key":"3381_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.smrv.2016.09.004","volume":"35","author":"A Kuriyama","year":"2017","unstructured":"Kuriyama A, Tabata H (2017) Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis. Sleep Med Rev 35:1\u20137. https:\/\/doi.org\/10.1016\/j.smrv.2016.09.004","journal-title":"Sleep Med Rev"},{"issue":"6","key":"3381_CR49","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1586\/17512433.2014.966813","volume":"7","author":"LH Jacobson","year":"2014","unstructured":"Jacobson LH, Callander GE, Hoyer D (2014) Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 7(6):711\u2013730. https:\/\/doi.org\/10.1586\/17512433.2014.966813","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"3381_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/10600280211008492","volume":"56","author":"K Waters","year":"2022","unstructured":"Waters K (2022) Review of the Efficacy and safety of lemborexant, a dual receptor orexin antagonist (DORA), in the treatment of adults with insomnia disorder. Ann Pharmacother 56(2):213\u2013221. https:\/\/doi.org\/10.1177\/10600280211008492","journal-title":"Ann Pharmacother"},{"key":"3381_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpsychires.2020.05.025","volume":"128","author":"T Kishi","year":"2020","unstructured":"Kishi T, Nomura I, Matsuda Y, Sakuma K, Okuya M, Ikuta T, Iwata N (2020) Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res 128:68\u201374. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.05.025","journal-title":"J Psychiatr Res"},{"issue":"2","key":"3381_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1474-4422(22)00007-2","volume":"21","author":"K Spiegelhalder","year":"2022","unstructured":"Spiegelhalder K, Feige B, Riemann D, Kyle SD (2022) Daridorexant for insomnia disorder. The Lancet Neurology 21(2):104\u2013105. https:\/\/doi.org\/10.1016\/S1474-4422(22)00007-2","journal-title":"The Lancet Neurology"},{"issue":"6","key":"3381_CR53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.12594","volume":"26","author":"D Riemann","year":"2017","unstructured":"Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Gon\u00e7alves M, Hertenstein E, Jansson-Fr\u00f6jmark M, Jennum PJ, Leger D, Nissen C, Parrino L, Paunio T, Pevernagie D, Verbraecken J, Wee\u00df HG, Spiegelhalder K (2017) European guideline for the diagnosis and treatment of insomnia. J Sleep Res 26(6):675\u2013700. https:\/\/doi.org\/10.1111\/jsr.12594","journal-title":"J Sleep Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03381-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03381-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03381-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T03:08:12Z","timestamp":1665112092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03381-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3381"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03381-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"14 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}